|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/24/2011 10:00:06 AM
VEDBAEK, Denmark, Aug. 24, 2011 (GLOBE NEWSWIRE) -- In a multicenter study, Exiqon, in collaboration with LEO Pharma, Bispebjerg Hospital, Gentofte Hospital, Copenhagen University Hospital and University of Copenhagen, has identified promising diagnostic biomarkers of cutaneous T cell lymphoma (CTCL) to distinguish between malignant and benign inflammation - i.e. between CTCL and chronic diseases such as psoriasis, atopic dermatitis and eczema. The results have been published in the well-esteemed journal "Blood, Journal of the American Society of Hematology", which is available at: http://bloodjournal.hematologylibrary.org/content/early/2011/08/23/blood-2011-06-358382
|
|
|
|
|
|
|
|
|
|
|